Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA+RC-BCG in CEA Positive Rectal Cancer
NCT02403505Phase 1Active, not recruiting
- Start
- Dec 2021
- Primary completion
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bcg vaccine in rectal cancer. Primary endpoints: Carcinoembryonic Antigen blood test at 90 days, Interferon-Gamma Release Assay blood test with CEA protein antigen at 90 days and 1 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
bcg vaccine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02403505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02403505.